Patents by Inventor Simona Cotesta

Simona Cotesta has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • NEW CRYSTALLINE FORMS OF A KRAS G12C INHIBITOR COMPOUND
    Publication number: 20240116900
    Abstract: Provided are crystalline forms of a KRAS G12C inhibitor compound and to processes for their preparation. Furthermore, provided is pharmaceutical composition comprising said crystalline forms, and at least one pharmaceutically acceptable excipient. The pharmaceutical composition can be used as a medicament, in particular for the treatment of cancer, and KRAS G12C-mutant cancer.
    Type: Application
    Filed: October 29, 2021
    Publication date: April 11, 2024
    Inventors: Simona COTESTA, Heng GE, Marc GERSPACHER, Catherine LEBLANC, Bo LIU, Edwige Liliane Jeanne LORTHIOIS, Rainer MACHAUER, Robert MAH, Tanja MEISTER, Christophe MURA, Pascal RIGOLLIER, Nadine SCHNEIDER, Stefan STUTZ, Andrea VAUPEL, Nicolas WARIN, Rainer WILCKEN, Lijun XUE, Marie-Anne LOZAC'H, Ross STRANG
  • PHARMACEUTICAL COMBINATIONS COMPRISING A KRAS G12C INHIBITOR AND USES OF A KRAS G12C INHIBITOR FOR THE TREATMENT OF CANCERS
    Publication number: 20240082218
    Abstract: It relates to a pharmaceutical combination comprising a KRAS G12C inhibitor, in particular 1-{6-[(4M)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro [3.3] heptan-2-yl} prop-2-en-1-one (Compound A) and one or more therapeutically active agents selected from a SHP2 inhibitor (e.g. TNO155) and a PD-1 inhibitor, pharmaceutical compositions comprising the same; and methods of using such combinations and compositions in the treatment or prevention of a cancer or a tumor, in particular wherein the cancer or tumor is KRAS G12C mutated.
    Type: Application
    Filed: December 20, 2021
    Publication date: March 14, 2024
    Inventors: Vasileios ASKOXYLAKIS, Saskia Maria BRACHMANN, Simona COTESTA, Xiaoming CUI, Jeffrey ENGELMAN, Anna FARAGO, Marc GERSPACHER, Diana GRAUS PORTA, Catherine LEBLANC, Edwige Liliane Jeanne LORTHIOIS, Bo LIU, Rainer MACHAUER, Robert MAH, Christophe MURA, Pascal RIGOLLIER, Nadine SCHNEIDER, Stefan STUTZ, Andrea Helga Emmi VAUPEL, Nicolas WARIN, Andreas WEISS, Rainer WILCKEN, Padmaja YERRAMILLI-RAO
  • Pyrazolyl derivatives useful as anti-cancer agents
    Patent number: 11702409
    Abstract: The present invention provides a compound of formula (I) or a stereoisomer thereof, or an atropisomer thereof, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable salt of a stereoisomer thereof, or a pharmaceutically acceptable salt of an atropisomer thereof; a method for manufacturing said compound, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition comprising said compound.
    Type: Grant
    Filed: December 17, 2020
    Date of Patent: July 18, 2023
    Assignee: NOVARTIS AG
    Inventors: Simona Cotesta, Marc Gerspacher, Catherine Leblanc, Edwige Liliane Jeanne Lorthiois, Bo Liu, Rainer Machauer, Robert Mah, Christophe Mura, Pascal Rigollier, Nadine Schneider, Stefan Stutz, Andrea Vaupel, Nicolas Warin, Rainer Wilcken
  • Pyrazolyl derivatives useful as anti-cancer agents
    Publication number: 20220363670
    Abstract: The present invention provides a compound of formula (I) or a stereoisomer thereof, or an atropisomer thereof, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable salt of a stereoisomer thereof, or a pharmaceutically acceptable salt of an atropisomer thereof; a method for manufacturing said compound, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition comprising said compound.
    Type: Application
    Filed: December 17, 2020
    Publication date: November 17, 2022
    Inventors: Simona Cotesta, Marc Gerspacher, Catherine Leblanc, Edwige Liliane Jeanne Lorthiois, Bo Liu, Rainer Machauer, Robert Mah, Christophe Mura, Pascal Rigollier, Nadine Schneider, Stefan Stutz, Andrea Vaupel, Nicolas Warin, Rainer Wilcken
  • Imidazopyrrolidine derivatives and their use in the treatment of disease
    Patent number: 9890166
    Abstract: The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof; a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.
    Type: Grant
    Filed: May 26, 2014
    Date of Patent: February 13, 2018
    Assignee: NOVARTIS AG
    Inventors: Jutta Blank, Guido Bold, Simona Cotesta, Vito Guagnano, Heinrich Rueeger, Andrea Vaupel
  • Pyrazolo-pyrrolidin-4-one derivatives and their use in the treatment of disease
    Patent number: 9714249
    Abstract: The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof; a method for manufacturing the pyrazolo-pyrrolidin-4-one derivatives, and their use as BET inhibitors for the treatment of conditions or diseases such as cancer. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.
    Type: Grant
    Filed: May 27, 2014
    Date of Patent: July 25, 2017
    Assignee: Novartis AG
    Inventors: Jutta Blank, Simona Cotesta, Vito Guagnano, Heinrich Rueeger
  • Pyrazolo-pyrrolidin-4-one derivatives as bet inhibitors and their use in the treatment of disease
    Patent number: 9624247
    Abstract: The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof; (1) a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.
    Type: Grant
    Filed: May 27, 2014
    Date of Patent: April 18, 2017
    Assignee: NOVARTIS AG
    Inventors: Jutta Blank, Guido Bold, Simona Cotesta, Vito Guagnano, Heinrich Rueeger
  • CARBOXAMIDE INHIBITORS
    Publication number: 20170088545
    Abstract: The present invention provides a compound of formula I The compounds of formula I demonstrate properties as Smurf-1 inhibitors and are thus useful in the treatment of a range of disorders, particularly pulmonary arterial hypertension.
    Type: Application
    Filed: May 14, 2015
    Publication date: March 30, 2017
    Applicant: Novartis AG
    Inventors: Luca ARISTA, Simona COTESTA, Pier D'ALESSANDRO, Anne-Marie EDWARDS, Rene LATTMANN, Dimitrios LIZOS, Robert Alexander PULZ, Lisa Ann ROONEY, Nichola SMITH, Jessica Louise TAYLOR, Thomas J. TROXLER
  • CARBOXAMIDE INHIBITORS
    Publication number: 20170088546
    Abstract: The present invention provides a compound of formula I The compounds of formula I demonstrate properties as Smurf-1 inhibitors and are thus useful in the treatment of a range of disorders, particularly pulmonary arterial hypertension.
    Type: Application
    Filed: May 14, 2015
    Publication date: March 30, 2017
    Applicant: NOVARTIS AG
    Inventors: Luca ARISTA, Rene BEERLI, Simona COTESTA, Pier Luca D'ALESSANDRO, Rene LATTMANN, Robert Alexander PULZ, Thomas J. TROXLER
  • Pyrrolopyrrolone derivatives and their use as BET inhibitors
    Patent number: 9550796
    Abstract: The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof; a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.
    Type: Grant
    Filed: November 20, 2014
    Date of Patent: January 24, 2017
    Assignee: NOVARTIS AG
    Inventors: Heinrich Rueger, Jutta Blank, Vincent Bordas, Simona Cotesta, Guido Bold, Vito Guagnano, Andrea Vaupel
  • PYRROLOPYRROLONE DERIVATIVES AND THEIR USE AS BET INHIBITORS
    Publication number: 20160280719
    Abstract: The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof; a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.
    Type: Application
    Filed: November 20, 2014
    Publication date: September 29, 2016
    Applicant: NOVARTIS AG
    Inventors: Jutta BLANK, Guido BOLD, Vincent BORDAS, Simona COTESTA, Vito GUAGNANO, Heinrich RUEGER, Andrea VAUPEL
  • Pyrrolopyrrolidinone compounds
    Patent number: 9365576
    Abstract: The invention relates to compounds of formula (I): as described herein, pharmaceutical preparations comprising such compounds, uses and methods of use for such compounds in the treatment of a disorder or a disease mediated by the activity of MDM2 and/or MDM4, and combinations comprising such compounds.
    Type: Grant
    Filed: May 22, 2013
    Date of Patent: June 14, 2016
    Assignee: Novartis AG
    Inventors: Simona Cotesta, Pascal Furet, Vito Guagnano, Philipp Holzer, Joerg Kallen, Robert Mah, Keiichi Masuya, Achim Schlapbach, Stefan Stutz, Andrea Vaupel
  • IMIDAZOPYRROLIDINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE
    Publication number: 20160108047
    Abstract: The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof; a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.
    Type: Application
    Filed: May 26, 2014
    Publication date: April 21, 2016
    Applicant: NOVARTIS AG
    Inventors: Jutta BLANK, Guido BOLD, Simona COTESTA, Vito GUAGNANO, Heinrich RUEEGER, Andrea VAUPEL
  • PYRAZOLO-PYRROLIDIN-4-ONE DERIVATIVES AS BET INHIBITORS AND THEIR USE IN THE TREATMENT OF DISEASE
    Publication number: 20160102107
    Abstract: The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof; (I) a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.
    Type: Application
    Filed: May 27, 2014
    Publication date: April 14, 2016
    Applicant: NOVARTIS AG
    Inventors: Jutta BLANK, Guido BOLD, Simona COTESTA, Vito GUAGNANO, Heinrich RUEEGER
  • PYRAZOLO-PYRROLIDIN-4-ONE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE
    Publication number: 20160096843
    Abstract: The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof; a method for manufacturing the pyrazolo-pyrrolidin-4-one derivatives, and their use as BET inhibitors for the treatment of conditions or diseases such as cancer. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.
    Type: Application
    Filed: May 27, 2014
    Publication date: April 7, 2016
    Applicant: NOVARTIS AG
    Inventors: Jutta BLANK, Simona COTESTA, Vito GUAGNANO, Heinrich RUEEGER
  • PYRAZOLOPYRROLIDINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE
    Publication number: 20160095843
    Abstract: The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof, a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.
    Type: Application
    Filed: May 26, 2014
    Publication date: April 7, 2016
    Applicant: NOVARTIS AG
    Inventors: Jutta BLANK, Vincent BORDAS, Simona COTESTA, Vito NANO, Heinrich RUEEGER, Andrea VAUPEL
  • Pyrazolopyrrolidine derivatives and their use in the treatment of disease
    Patent number: 8975417
    Abstract: The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof; a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.
    Type: Grant
    Filed: May 20, 2014
    Date of Patent: March 10, 2015
    Assignee: Novartis AG
    Inventors: Vincent Bordas, Simona Cotesta, Vito Guagnano, Heinrich Rueeger, Andrea Vaupel
  • Pyrazolopyrrolidine Derivatives and their Use in the Treatment of Disease
    Publication number: 20140349990
    Abstract: The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof; a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.
    Type: Application
    Filed: May 20, 2014
    Publication date: November 27, 2014
    Applicant: NOVARTIS AG
    Inventors: Jutta BLANK, Vincent BORDAS, Simona COTESTA, Vito GUAGNANO, Heinrich RUEEGER, Andrea VAUPEL
  • Disubstituted heteroaryl-fused pyridines
    Patent number: 8742106
    Abstract: The invention relates to compound of the formula (I?) in which the substituents are as defined in the specification; in free form or in salt form; to its preparation, to its use as medicament and to medicaments comprising it.
    Type: Grant
    Filed: December 20, 2010
    Date of Patent: June 3, 2014
    Assignee: Novartis AG
    Inventors: Sangamesh Badiger, Dirk Behnke, Claudia Betschart, Vinod Chaudhari, Murali Chebrolu, Simona Cotesta, Samuel Hintermann, Arndt Meyer, Chetan Pandit
  • PYRROLOPYRROLIDINONE COMPOUNDS
    Publication number: 20130317024
    Abstract: The invention relates to compounds of formula (I): as described herein, pharmaceutical preparations comprising such compounds, uses and methods of use for such compounds in the treatment of a disorder or a disease mediated by the activity of MDM2 and/or MDM4, and combinations comprising such compounds.
    Type: Application
    Filed: May 22, 2013
    Publication date: November 28, 2013
    Applicant: NOVARTIS AG
    Inventors: Simona Cotesta, Pascal Furet, Vito Guagnano, Philipp Holzer, Joerg Kallen, Robert Mah, Keiichi Masuya, Achim Schlapbach, Stefan Stutz, Andrea Vaupel